Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 7:15:257-284.
doi: 10.1146/annurev-clinpsy-050718-095634. Epub 2019 Jan 30.

Augmentation of Extinction and Inhibitory Learning in Anxiety and Trauma-Related Disorders

Affiliations
Review

Augmentation of Extinction and Inhibitory Learning in Anxiety and Trauma-Related Disorders

Lauren A M Lebois et al. Annu Rev Clin Psychol. .

Abstract

Although the fear response is an adaptive response to threatening situations, a number of psychiatric disorders feature prominent fear-related symptoms caused, in part, by failures of extinction and inhibitory learning. The translational nature of fear conditioning paradigms has enabled us to develop a nuanced understanding of extinction and inhibitory learning based on the molecular substrates to systems neural circuitry and psychological mechanisms. This knowledge has facilitated the development of novel interventions that may augment extinction and inhibitory learning. These interventions include nonpharmacological techniques, such as behavioral methods to implement during psychotherapy, as well as device-based stimulation techniques that enhance or reduce activity in different regions of the brain. There is also emerging support for a number of psychopharmacological interventions that may augment extinction and inhibitory learning specifically if administered in conjunction with exposure-based psychotherapy. This growing body of research may offer promising novel techniques to address debilitating transdiagnostic fear-related symptoms.

Keywords: PTSD; amygdala; exposure; extinction; fear conditioning; inhibitory learning.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURE STATEMENT

K.J.R. is on the scientific advisory boards of Resilience Therapeutics, the Sheppard Pratt-Lieber Research Institute, the Laureate Institute for Brain Research, the Army Study to Assess Risk and Resilience in Servicemembers (STARRS) project, the University of California San Diego VA Center of Excellence for Stress and Mental Health (CESAMH), and the Anxiety and Depression Association of America. He provides fee-for-service consultation for Biogen and Resilience Therapeutics. He holds patents for the use of d-cycloserine and psychotherapy, targeting the pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor for extinction, targeting tachykinin 2 for prevention of fear and targeting angiotensin to improve extinction of fear. L.A.M.L., A.V.S., J.D.W., and S.B.H. declare no competing interests.

References

    1. Abraham AD, Cunningham CL, Lattal KM. 2012. Methylphenidate enhances extinction of contextual fear. Learn. Mem 19(2):67–72 - PMC - PubMed
    1. Abraham AD, Neve KA, Lattal KM. 2014. Dopamine and extinction: a convergence of theory with fear and reward circuitry. Neurobiol. Learn. Mem 108:65–77 - PMC - PubMed
    1. Alvarez-Dieppa AC, Griffin K, Cavalier S, McIntyre CK. 2016Vagus nerve stimulation enhances extinction of conditioned fear in rats and modulates Arc protein, CaMKII, and GluN2B-containing NMDA receptors in the basolateral amygdala. Neural Plast. 2016:4273280. - PMC - PubMed
    1. Amenta F, Mignini F, Rabbia F, Tomassoni D, Veglio F. 2002. Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: analysis of published clinical data. J. Neurol. Sci 203–4:147–51 - PubMed
    1. Anderson C, Teo K, Gao P, Arima H, Dans A, et al. 2011. ONTARGET and TRANSCEND investigators. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 10(1):43–53 - PubMed

Publication types

MeSH terms